2019
DOI: 10.13005/bpj/1799
|View full text |Cite
|
Sign up to set email alerts
|

Dipeptidyl Peptidase IV: A Target for Improving Metabolic Syndrome Components in Obese Children and Adolescents

Abstract: Dipeptidyl peptidase-IV (DPP-IV) is a circulating glycoprotein that reduces uptake of insulin-stimulated glucose and is related to obesity and metabolic syndrome. However, the influence of exercise and nutritional plan on serum DPP-IV in children and adolescents with metabolic syndrome remains unclear. To judge serum activity of DPP-IV in obese children and adolescents with and without metabolic syndrome, and to assess the impact of exercise, and nutritional regimen on serum DPP-IV activity, metabolic syndrome… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 44 publications
0
1
0
Order By: Relevance
“…Thus, DPP-IV inhibitors can extend GLP-1 and GIP action, and also enhance blood glucose regulation, which is considered a novel treatment against T2D [ 58 ]. DPP-IV activity has been related to metabolic syndrome (MS) in obese children and adolescents by El-Alameey et al [ 60 ], where serum DPP-IV activity of obese patients with MS was significantly elevated in relation to obese patients without MS and control subjects. Trzaskalski et al [ 61 ] also attributed to DDP-IV an important role in metabolic disease.…”
Section: Resultsmentioning
confidence: 99%
“…Thus, DPP-IV inhibitors can extend GLP-1 and GIP action, and also enhance blood glucose regulation, which is considered a novel treatment against T2D [ 58 ]. DPP-IV activity has been related to metabolic syndrome (MS) in obese children and adolescents by El-Alameey et al [ 60 ], where serum DPP-IV activity of obese patients with MS was significantly elevated in relation to obese patients without MS and control subjects. Trzaskalski et al [ 61 ] also attributed to DDP-IV an important role in metabolic disease.…”
Section: Resultsmentioning
confidence: 99%